Home > Formulary : Adult > Recent Decisions > 2014 >
Decisions 22nd April 2014
Recent JFG Decisions
At the meeting on the 22nd April 2014 the following decisions / changes to the formulary were agreed:
New Drug Requests
Approved
Relvar®
- Approved for use in asthma and COPD when FEV1 <50%.
Dexmedetomidine
- Approved for inclusion onto the formulary for use in NBT during awake craniotomies.
Dexmedetomidine
- Approved for inclusion onto the formulary for sedation in Paediatric Intensive Care, UHBristol
Colobreathe® inhaler
- Approved for inclusion onto the formulary for the treatment of non-Cystic Fibrosis bronchiectasis patients who require treatment with colistimethate sodium but are unable to tolerate or comply with nebulisers.
Regadenoson
- Approved for inclusion onto the formulary for use in stress myocardial perfusion imagine scans
Rejected
Dapoxetine
- Rejected - the JFG considered dapoxetine not to be cost-effective option for the treatment of Premature ejacultaion.
More information required
Botulinum toxin A for the treatment of urinary incontinence
- Clinically accepted, funding needs agreement.
Alogliptin
- Needs full review of the class 'gliptins' to ensure that the formulary can identify recommended and alternative options.
Linaclotide
- Provisionally agreed, amber 1 month, SCP required.
Specialised Commissioning
None
Shared Care Protocols/TLS Change in Status
Rasagiline
- TLS change from amber 3 months to green rejected. However the JFG approved a change to amber 1 month, and SCP to be altered.
Stalevo®
- TLS change from amber 3 months to green rejected. However the JFG approved a change to amber 1 month, and SCP to be altered.
Entacapone
- TLS change from amber 3 months to green rejected. However the JFG approved a change to amber 1 month, and SCP to be altered.
Rufinamide
- TLS change from Red to amber 3 months accepted and new SCP.
Perampanel
- TLS change from Red to amber 3 months accepted and new SCP.